New Treatment Methods in Multiple Myeloma

1. Provan D, Baglin T, Dokal I, et al. Oxford Handbook of Clinical Haematology, 4th ed. Oxford University Press, 2015; p. 336-361.10.1093/med/9780199683307.001.0001Search in Google Scholar

2. Palumbo A, Cerrato C. Diagnosis and therapy of multiple myeloma. Korean J Intern Med. 2013;28:263-273.10.3904/kjim.2013.28.3.263365412123682217Search in Google Scholar

3. Bergsage D, Sprague C, Austin C, et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NC-8806). Cancer Chemotherapy Rep. 1962;21:87.Search in Google Scholar

4. Rosignol L, Oriol A, Terulel A, et al. Superiority of bortezomib, thalidomide and dexamethasone as induction pre-transplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589-1596.10.1182/blood-2012-02-40892222791289Search in Google Scholar

5. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m² melphalan and 8 Gy total body irradiation plus 140 mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM95-02 randomized trial. Blood. 2002;99:731-735.10.1182/blood.V99.3.731Search in Google Scholar

6. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.10.1182/blood.V89.3.789Search in Google Scholar

7. Harousseau J. High-dose therapy in multiple myeloma. Annals of Oncology. 2002;13:49-54.10.1093/annonc/mdf63812401666Search in Google Scholar

8. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.10.1056/NEJM19991118341210210564685Search in Google Scholar

9. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28:2077-2084.10.1200/JCO.2009.23.717220308672Search in Google Scholar

10. Greipp P, Miguel J, Dune B, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.10.1200/JCO.2005.04.24215809451Search in Google Scholar

11. Kyle R, Rajkumar S. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9.10.1038/leu.2008.291262778618971951Search in Google Scholar

12. Dispenzieri A, Rajkumar S, Gertz M, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and riskadapted therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323-341.10.1016/S0025-6196(11)61029-XSearch in Google Scholar

13. Lee H, Min CK. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Korean J Intern Med. 2016;31:809-819.10.3904/kjim.2016.110501629227604793Search in Google Scholar

14. Kyle R, Rajkumar S. Treatment of Multiple Myeloma: A Comprehensive Review. Clin Lymphoma Myeloma. 2009;9:278-288.10.3816/CLM.2009.n.056391014219717377Search in Google Scholar

15. Uy G, Rettig M, Cashen A. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008;8:1797-1804.10.1517/14712598.8.11.179718847313Search in Google Scholar

16. Mehdizadeh M, Hajifathali A, Tabarraee M, et al. Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran. Iran J Pharm Res. 2013;12:189-191.Search in Google Scholar

17. Kouroukis C, Varela N, Bredeson C, et al. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Curr Oncol. 2016;23:409-430.10.3747/co.23.3137497404727536190Search in Google Scholar

18. Lázár E, Köpeczi J, Kakucs E, et al. Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients. Journal of Interdisciplinary Medicine. 2017;2:41-44.10.1515/jim-2017-0028Search in Google Scholar

19. Lázár E, Găzdac M, Jakab S, et al. Double Autologous Stem Cell Transplantation in a Case of nonsecretory Multiple Myeloma. Journal of Interdisciplinary Medicine. 2016;1:297-299.10.1515/jim-2016-0058Search in Google Scholar

20. Stewart A, Bergsagel P, Greipp P, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21:529-534.10.1038/sj.leu.240451617230230Search in Google Scholar

21. McCarthy P, Owzar K, Hofmeister C, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770-1781.10.1056/NEJMoa1114083374439022571201Search in Google Scholar

22. Attal M, Harousseau J, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289-3294.10.1182/blood-2006-05-02296216873668Search in Google Scholar

23. Palumbo A, Bringhen S, Liberati A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112:3107-3114.10.1182/blood-2008-04-149427Search in Google Scholar

24. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946-2955.10.1200/JCO.2011.39.6820Search in Google Scholar

25. Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113:1020-1034.10.1046/j.1365-2141.2001.02857.xSearch in Google Scholar

26. Barlogie B, Kyle R, Anderson K, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929-936.10.1200/JCO.2005.04.5807Search in Google Scholar

27. Jagannath S, Durie B, Wolf J Jr, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood. 2006;108:238a-239a.10.1182/blood.V108.11.796.796Search in Google Scholar

28. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.10.1056/NEJMoa053583Search in Google Scholar

29. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115-121.10.1182/blood-2008-03-145235Search in Google Scholar

30. San Miguel J, Schlag R, Khuageva N, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.10.1056/NEJMoa0801479Search in Google Scholar

31. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32: 2712-2717.10.1200/JCO.2013.54.8164Search in Google Scholar

32. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333-342.10.1016/S1470-2045(13)70609-0Search in Google Scholar

33. Benedek Lazar E, Benedek I, Benedek I Jr., et al. Double Hematological and Cardiologic Benefits of Autologous Stem Cell Transplantation in a Case of stage III B IgG Myeloma multiplex and Dilatative Cardiomyopathy – a Case Report. ARS Medica Tomitana. 2015;21:223-226.10.1515/arsm-2015-0050Search in Google Scholar

34. Usmani S, Crowley J, Hoering A, et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured? Leukemia. 2013;27:226-232.Search in Google Scholar

35. Rizzo J, Somerfield M, Hagerty K, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132-149.10.1200/JCO.2007.14.339617954713Search in Google Scholar

36. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28:2077-2084.10.1200/JCO.2009.23.717220308672Search in Google Scholar

37. Chng W, Dispenzieri A, Chim C, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269-277.10.1038/leu.2013.24723974982Search in Google Scholar

38. Palumbo A, Rajkumar S, Dimopoulos M, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-423.10.1038/sj.leu.240506218094721Search in Google Scholar